Markets:

Overview

News

Currencies

International

Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

33.51 -0.93 (-2.70%)

Official Closing Price Updated: 7:00 PM EDT, May 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

March 31, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

March 06, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

March 03, 2025

From QIAGEN N.V.

Via Business Wire

Qiagen Earnings Review: Q4 Summary ↗

February 05, 2025

Via Benzinga

Qiagen: Q4 Earnings Insights ↗

February 05, 2025

Via Benzinga

Earnings Scheduled For February 5, 2025 ↗

February 05, 2025

Via Benzinga

2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62% ↗

February 23, 2025

Via The Motley Fool

This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

February 19, 2025

Via Benzinga

QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region

February 13, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN delivers solid Q4 2024 growth ahead of outlook

February 05, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent

February 04, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million

January 16, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

January 15, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

January 12, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

January 10, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

January 09, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content

January 07, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data

December 12, 2024

From QIAGEN N.V.

Via Business Wire

QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation

December 05, 2024

From QIAGEN N.V.

Via Business Wire

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

November 28, 2024

From QIAGEN N.V.

Via Business Wire

18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker' ↗

October 10, 2024

Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500.

Via Benzinga

Topics Stocks

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

August 06, 2024

From Myriad Genetics, Inc.

Via GlobeNewswire

Strategic Buy Lights Up This Biotech Stock: Time to Invest?

July 16, 2024

Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences.

Via MarketBeat

FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation ↗

June 24, 2024

The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer.

Via Benzinga

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 20, 2024

Via Benzinga

Qiagen Unveils Plan For $1B Shareholder Returns, Major Product Launches ↗

June 17, 2024

QIAGEN announces a comprehensive growth strategy by 2028. The plan includes significant shareholder returns, new product launches, and a focus on digital and diagnostic advancements.

Via Benzinga

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

May 30, 2024

From Myriad Genetics, Inc.

Via GlobeNewswire

QGEN Stock Earnings: Qiagen Beats EPS, Beats Revenue for Q1 2024 ↗

April 29, 2024

QGEN stock results show that Qiagen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report ↗

May 06, 2024

According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far.

Via Benzinga

Topics Stocks

US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday? ↗

April 29, 2024

U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc....

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.